Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6531
    +0.0030 (+0.47%)
     

  • OIL

    82.97
    +0.16 (+0.19%)
     

  • GOLD

    2,341.70
    +3.30 (+0.14%)
     

  • Bitcoin AUD

    97,773.37
    -4,169.99 (-4.09%)
     

  • CMC Crypto 200

    1,358.67
    -23.90 (-1.73%)
     

  • AUD/EUR

    0.6091
    +0.0021 (+0.34%)
     

  • AUD/NZD

    1.0957
    +0.0015 (+0.14%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,094.53
    +54.15 (+0.67%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,969.24
    -119.46 (-0.66%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Immutep to Participate in the JMP Securities Life Sciences Conference

Immutep Limited
Updated ·1-min read
Immutep Limited
Immutep Limited

Media Release

SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present and be available for 1-on-1 meetings at the JMP Securities Life Sciences Conference, on Tuesday, May 16th, 2023. Presentation details:

The JMP Securities Life Sciences Conference
Location: New York Hilton Midtown, 1335 Avenue of the Americas
Date: Tuesday, May 16th
Presentation time: 3:00PM ET

ADVERTISEMENT

About Immutep
Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Investors/Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com